Rapid reduction of viruria and stabilization of allograft function by fusidic acid in a renal transplant recipient with JC virus-associated nephropathy

• Published in: Infection 2015-10, Vol.43 (5), p.577-581
• Main Authors: Chan, Jasper Fuk-Woo, Ma, Maggie Kam-Man, Chan, Gavin Shueng-Wai, Chan, Gary Chi-Wang, Choi, Garnet Kwan-Yue, Chan, Kwok-Hung, Cheng, Vincent Chi-Chung, Chan, Kwok-Wah, Choy, Bo-Ying, Yuen, Kwok-Yung
• Format: Article
• Language: English
• Subjects: Administration, Oral; Allografts - physiology; Anti-Infective Agents - administration & dosage; Bioavailability; Case Report; Family Medicine; Fusidic Acid - administration & dosage; General Practice; Humans; Infectious Diseases; Internal Medicine; JC virus; JC Virus - isolation & purification; Kidney transplantation; Kidney Transplantation - adverse effects; Male; Medicine; Medicine & Public Health; Polyomavirus Infections - drug therapy; Polyomavirus Infections - virology; Real-Time Polymerase Chain Reaction; Renal function; Transplant Recipients; Treatment Outcome; Urine - virology
• ISSN: 0300-8126; 1439-0973
• DOI: 10.1007/s15010-015-0721-x

JC virus (JCV)-associated nephropathy has been increasingly recognized as a cause of allograft dysfunction with graft loss in renal transplant recipients. Like many other opportunistic viral infections in transplant recipients, there are currently limited therapeutic options for this condition. Fusidic acid has previously been reported to exhibit antiviral activity against JCV in in vitro assays. We report the first in vivo study to document the rapid reduction of JC viruria and stabilization of allograft function by oral fusidic acid (fusidate sodium) in a deceased donor renal transplant recipient with JCV-associated nephropathy and acute allograft dysfunction which did not improve initially to surgical relief of hydronephrosis and reduction of immunosuppressants. Rapid reduction of JC viruria detected by quantitative PCR and stabilization of renal function were observed. Fusidic acid has several practical advantages in this clinical setting, including a low EC 50 against JCV, high plasma C max , long half-life, availability of both oral and intravenous formulations, excellent oral bioavailability, good patient tolerability, and lack of serious drug interactions with other drugs taken by renal transplant recipients. Further mechanistic and clinical studies are necessary to evaluate this treatment option for JCV-associated nephropathy.